Method/ology of Phases of Biomarker Discovery

被引:2
|
作者
Navanandan, Nidhya [1 ]
Searns, Justin [2 ,3 ,4 ]
Ambroggio, Lilliam [1 ,2 ]
机构
[1] Childrens Hosp Colorado, Sect Emergency Med, Aurora, CO USA
[2] Childrens Hosp Colorado, Sect Hosp Med, Aurora, CO USA
[3] Childrens Hosp Colorado, Sect Infect Dis, Aurora, CO USA
[4] Univ Colorado, Dept Pediat, Aurora, CO USA
基金
美国国家卫生研究院;
关键词
ASTHMA;
D O I
10.1542/hpeds.2022-007012
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Biomarkers are commonly used in pediatric medicine to identify disease and guide clinical management for children. Biomarkers can be used to predict risk of disease, provide diagnostic clarification, and offer prognostic expectations. Specimens for biomarker testing might require noninvasive collection (eg, urine, exhaled breath) or invasive procedures (eg, blood, bronchoalveolar lavage) and testing might use various methodologies (eg, genomics, transcriptomics, proteomics, metabolomics). Specimen type and testing methodology depends on the disease of interest, ability to obtain sample, and availability of biomarker testing. To develop a new biomarker, researchers must first identify and validate the target, and then determine the test characteristics of the biomarker. Once it has undergone initial development and testing, a new biomarker is then tested in the clinical setting before being implemented into practice. An ideal biomarker is one that is feasible to obtain, readily quantifiable, and offers meaningful information that impacts care. Learning how to reliably interpret the performance and clinical application of a new biomarker is an important skillset for all pediatricians in the hospital setting. Here we provide a high-level overview of the process from biomarker discovery to application. In addition, we provide an example for the real-world application of biomarkers as an opportunity for clinicians to build on their ability to critically evaluate, interpret, and implement biomarkers in clinical practice.
引用
收藏
页码:e181 / e185
页数:5
相关论文
共 50 条
  • [21] Streamlining biomarker discovery
    Latterich, Martin
    Schnitzer, Jan E.
    NATURE BIOTECHNOLOGY, 2011, 29 (07) : 600 - 602
  • [22] Degradomics in Biomarker Discovery
    Grozdanic, Marija
    Vidmar, Robert
    Vizovisek, Matej
    Fonovic, Marko
    PROTEOMICS CLINICAL APPLICATIONS, 2019, 13 (06)
  • [23] Method of enrichment of human plasma extracellular vesicles for reliable quantification for biomarker discovery
    Holcar, M.
    Ferdin, J.
    Sitar, S.
    Tusek-Znidaric, M.
    Dolzan, V.
    Plemenitas, A.
    Zagar, E.
    Lenassi, M.
    FEBS OPEN BIO, 2021, 11 : 223 - 223
  • [24] Computational method for discovery of biomarker signatures from large, complex data sets
    Makarov, Vladimir
    Gorlin, Alex
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2018, 76 : 161 - 168
  • [25] Application of a High Throughput Method of Biomarker Discovery to Improvement of the EarlyCDT®-Lung Test
    Macdonald, Isabel K.
    Murray, Andrea
    Healey, Graham F.
    Parsy-Kowalska, Celine B.
    Allen, Jared
    McElveen, Jane
    Robertson, Chris
    Sewell, Herbert F.
    Chapman, Caroline J.
    Robertson, John F. R.
    PLOS ONE, 2012, 7 (12):
  • [26] Analyzing biomarker discovery: Estimating the reproducibility of biomarker sets
    Forouzandeh, Amir
    Rutar, Alex
    Kalmady, Sunil V.
    Greiner, Russell
    PLOS ONE, 2022, 17 (07):
  • [27] Novel technique for biomarker discovery
    Miller, Christine
    Miller, Bryan
    Michnowicz, John
    GENETIC ENGINEERING NEWS, 2006, 26 (14): : 40 - +
  • [28] Capitalizing on biomarker discovery work
    Stokes, Trevor
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2008, 28 (02): : 40 - +
  • [29] Protein biomarker discovery in plasma
    Witonsky, Jonathan
    GENETIC ENGINEERING NEWS, 2006, 26 (18): : 5 - 5
  • [30] Metabolomics and Cardiovascular Biomarker Discovery
    Rhee, Eugene P.
    Gerszten, Robert E.
    CLINICAL CHEMISTRY, 2012, 58 (01) : 139 - 147